Basel, Switzerland – 6 May 2025 > CordenPharma is proud to announce that the Science-Based Targets initiative (SBTi) has officially approved the group’s near-term greenhouse gas (GHG) emission reduction targets. Following a two-year carbon footprint measurement process resulting in a submission of the targets in November 2024, the SBTi’s Target Validation Team has confirmed that the group’s ambition is in conformance with the SBTi Standards and Guidance.
This milestone reflects CordenPharma’s commitment to climate action and underscores its leadership in sustainable pharmaceutical manufacturing.
CordenPharma’s Approved Near-Term Science-Based Targets:
*The target boundary includes land-related emissions and removals from bioenergy feedstocks.
The SBTi provides a clear and science-based framework for companies to set emissions reduction targets that support global efforts to limit warming to 1.5°C above pre-industrial levels. For CordenPharma, this validation reinforces its dedication to establishing sustainable practices that support pharma and biotech innovators with the complex modalities they need to improve patient outcomes, while contributing to a healthier planet.
CordenPharma’s Climate Aims Moving Forward:
William Cashin, Chief Quality & Compliance Officer at CordenPharma, commented: “Our sustainability teams across all global sites have worked with passion and diligence to develop robust emission reduction targets. Receiving SBTi approval marks a major milestone in our climate journey. With the full support of our shareholders Astorg, we are united in our ambition to lead in climate action and provide greater transparency to our customers, employees, and stakeholders. This validation strengthens our role as a trusted CDMO partner—one that prioritizes environmental responsibility alongside service excellence.”
CordenPharma joins more than 7000 companies and financial institutions setting science-based targets.
CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.
With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).
The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2024 financial year, the organization generated sales of €854 million and had over 3,000 employees. In 2022, CordenPharma was acquired by Astorg – a leading Pan-European private equity firm with deep expertise in the healthcare sector – to accelerate its development and further strengthen its leadership as a CDMO.
Please visit cordenpharma.com for more information I Follow CordenPharma on LinkedIn.
CordenPharma Media Contacts
North America: abby.thompson@cordenpharma.com I Europe & Asia: eva.schaub@cordenpharma.com
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.